AbbVie Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ABBV research report →
Companywww.abbvie.com
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.
- CEO
- Robert A. Michael
- IPO
- 2013
- Employees
- 55,000
- HQ
- North Chicago, IL, US
Price Chart
Valuation
- Market Cap
- $375.13B
- P/E
- 103.50
- P/S
- 5.97
- P/B
- 13.70
- EV/EBITDA
- 24.42
- Div Yield
- 3.17%
Profitability
- Gross Margin
- 73.46%
- Op Margin
- 27.60%
- Net Margin
- 5.79%
- ROE
- 68.01%
- ROIC
- 10.29%
Growth & Income
- Revenue
- $61.16B · 8.57%
- Net Income
- $4.23B · -1.22%
- EPS
- $2.37 · -1.25%
- Op Income
- $20.09B
- FCF YoY
- -0.09%
Performance & Tape
- 52W High
- $244.81
- 52W Low
- $180.25
- 50D MA
- $209.07
- 200D MA
- $218.98
- Beta
- 0.30
- Avg Volume
- 6.78M
Get TickerSpark's AI analysis on ABBV
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 8, 26 | FALK THOMAS J | other | 1,118 |
| May 8, 26 | WADDELL FREDERICK H | other | 1,118 |
| May 8, 26 | Roberts Rebecca B | other | 1,118 |
| May 8, 26 | RAPP EDWARD J | other | 1,118 |
| May 8, 26 | Quaggin Susan E | other | 1,118 |
| May 8, 26 | MEYER MELODY B | other | 1,118 |
| May 8, 26 | Hart Brett J | other | 1,118 |
| May 8, 26 | FREYMAN THOMAS C | other | 1,118 |
| May 8, 26 | Davis Jennifer L. | other | 1,118 |
| May 8, 26 | BURNSIDE WILLIAM H.L. | other | 1,118 |
Our ABBV Coverage
We haven't published any research on ABBV yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ABBV Report →